

AMENDMENTS TO THE CLAIMS

1 - 87. (cancelled)

<sup>1</sup>~~88~~. (currently amended) An isolated monoclonal antibody or fragment thereof that specifically binds to a protein comprising the amino acid sequence of SEQ ID NO: 728, wherein the antibody or fragment thereof is conjugated to a diagnostic agent or a cytotoxic agent.

89. (cancelled)

<sup>2</sup>~~90~~. (previously presented) The antibody or fragment thereof of claim <sup>1</sup>~~88~~, wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody.

<sup>3</sup>~~91~~. (previously presented) The antibody or fragment thereof of claim <sup>1</sup>~~88~~, wherein the fragment is an Fab, F(ab')<sub>2</sub>, Fv or sFv fragment.

92-93. (cancelled)

<sup>4</sup>~~94~~. (previously presented) The antibody or fragment thereof of claim <sup>1</sup>~~88~~ <sup>1</sup>~~93~~, wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes, chemotherapeutic agents and toxins.

<sup>5</sup>~~95~~. (previously presented) The antibody or fragment thereof of claim <sup>4</sup>~~94~~, wherein the radioactive isotope is selected from the group consisting of <sup>211</sup>At, <sup>131</sup>I, <sup>125</sup>I, <sup>90</sup>Y, <sup>186</sup>Re, <sup>188</sup>Re, <sup>153</sup>Sm, <sup>212</sup>Bi, <sup>32</sup>P and radioactive isotopes of Lu.

<sup>6</sup>~~96~~. (previously presented) The antibody or fragment thereof of claim <sup>4</sup>~~94~~, wherein the chemotherapeutic agent is selected from the group consisting of ~~taxol~~ actinomycin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin.

~~7~~<sup>4</sup> ~~96~~. (previously presented) The antibody or fragment thereof of claim ~~94~~<sup>4</sup>, wherein the toxin is selected from the group consisting of diphtheria toxin, enomycin, phenomycin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, mitogellin, modeccin A chain, and alpha-sarcin.

~~8~~<sup>1</sup> ~~98~~. (previously presented) The antibody or fragment thereof of claim ~~98~~<sup>1</sup>, wherein the antibody or fragment thereof further comprises a pharmaceutically acceptable carrier.